文献速递炎症性肠病

妊娠期皮质类固醇暴露与IBD母亲婴儿不良围产结局相关:PIANO登记研究

Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry.
PubMed 文献 · Gut · 2021-10-22

基于PIANO前瞻性登记研究,纳入1490名IBD孕妇及1431例活产,评估妊娠期皮质类固醇暴露对不良妊娠结局的影响。调整多因素模型显示,皮质醇暴露与早产(OR 1.79)、低出生体重(OR 1.76)及NICU入住(OR 1.54)风险增加相关;孕中晚期使用与9、12月龄严重感染相关,发育里程碑无差异。

要点

  • 妊娠期皮质类固醇暴露增加IBD孕妇早产、低出生体重和NICU入住风险。
  • 孕中晚期使用皮质类固醇与婴儿9和12月龄严重感染风险升高相关。
  • 皮质类固醇暴露组与未暴露组发育里程碑相似,但唇裂病例数在暴露组更多。

核心结论

  • IBD孕妇妊娠期皮质类固醇暴露与早产、低出生体重和NICU入住风险增加独立相关。
  • 孕中晚期皮质类固醇暴露与婴儿9和12月龄严重感染风险升高相关。
  • 研究强调孕前及孕期通过非类固醇疗法控制疾病活动的重要性。

研究设计与样本

  • 前瞻性队列研究,使用PIANO登记数据,于每个孕期、分娩时及产后12个月收集数据。
  • 共纳入1490名IBD孕妇,记录1431例活产。
  • 采用双变量统计和多变量logistic回归模型比较皮质类固醇暴露组与未暴露组的妊娠结局。

主要发现

  • 皮质类固醇使用与早产风险增加相关(调整OR 1.79,95%CI 1.18至2.73)。
  • 皮质类固醇使用与低出生体重风险增加相关(调整OR 1.76,95%CI 1.07至2.88)。
  • 皮质类固醇使用与NICU入住风险增加相关(调整OR 1.54,95%CI 1.03至2.30)。
  • 孕中晚期皮质类固醇使用与9月龄严重感染相关(4% vs 2%,p=0.03)。
  • 孕中晚期皮质类固醇使用与12月龄严重感染相关(5% vs 2%,p=0.001)。

临床怎么用

  • 对IBD孕妇应优先采用非类固醇疗法控制疾病活动,以减少皮质类固醇暴露相关不良围产结局。
  • 孕期需使用皮质类固醇时,应告知患者早产、低出生体重、NICU入住及婴儿感染风险可能增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Active inflammatory bowel disease (IBD) during pregnancy may require the use of corticosteroids. The aim of this study was to investigate the impact of in utero corticosteroid exposure on adverse pregnancy outcomes, congenital malformations, infections and neurocognitive development among offspring of mothers with IBD. DESIGN: Using the prospective Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes registry, data were collected at each trimester, delivery; and in the 12 months post partum. Bivariate statistics and multivariate logistic regression models compared pregnancy outcomes by corticosteroid exposure. RESULTS: A total of 1490 mothers with IBD were enrolled, with 1431 live births recorded. Corticosteroid use was associated with increased risk of preterm birth, small for gestational age, low birth weight (LBW), intrauterine growth restriction and neonatal intensive care unit (NICU) admission. On adjusted multivariate models, corticosteroid use was associated with preterm birth (OR 1.79, 95% CI 1.18 to 2.73), LBW (OR 1.76, 95% CI 1.07 to 2.88) and NICU admission (OR 1.54, 95% CI 1.03 to 2.30). Late corticosteroid use (second and/or third trimester) was associated with serious infections at 9 and 12 months (4% vs 2% and 5% vs 2%, respectively, p=0.03 and p=0.001). There were five newborns with in utero corticosteroid exposure born with orofacial clefts versus one without corticosteroid exposure. Developmental milestones were similar across corticosteroid exposure groups. CONCLUSION: In this prospective pregnancy registry, offspring of women exposed to corticosteroids during pregnancy were more likely to have adverse pregnancy outcomes. This emphasises the importance of controlling disease activity before and during pregnancy with steroid-sparing therapy.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Odufalu FD, Long M, Lin K, et al. Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry. Gut. 2021. PMID: 34686575. doi:10.1136/gutjnl-2021-325317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。